JSM2023
Back to the program
Contributed Papers

Dose Finding in Early Oncology Clinical Trials

Mon, Aug 7, 10:30 AM
Bob ZhongChair
Biopharmaceutical Section

7 Presentations

A Hybrid Design for Dose-Finding Oncology Clinical Trials
10:35 AM - 10:50 AM
Feng Zhou
Co-authors: Jason JZ Liao (Incyte Corporation)
Bayesian Model Averaging Bayesian Logistic Regression Model with Overdose Control in Dose-Escalation
10:50 AM - 11:05 AM
Chaoqun Mei
Co-authors: Shaoyi Li (BMS), Alan Chiang (Lyell Immunopharma), Hongtao Zhang
Identification of potential optimal dose via joint modeling of efficacy and safety information
11:05 AM - 11:20 AM
Yiding Zhang
Co-authors: Ji Lin (Sanofi), Gu Mi (Sanofi), Federico Rotolo (Sanofi), Wenting Wang (Sanofi)
Innovative strategies to enhance dose optimization in oncology drug development
11:20 AM - 11:35 AM
Jiani Yin (Takeda)
Co-authors: Yunqi Zhao, Meizi Liu (The University of Chicago), Jianchang Lin (Takeda), Rachael Liu
Model-based approach to design of a series of Phase I/II studies of multiple treatment combinations
11:35 AM - 11:50 AM
Bethany Horton (University of Virginia)
Co-authors: Michael Keng (The University of Virginia), Cara Hanby (The University of Virginia)
Optimal dose finding in Oncology: simultaneous or sequential utilization of safety and efficacy?
11:50 AM - 12:05 PM
Ran Li (Astellas)
Co-authors: Kentaro Takeda (Astellas Pharma Global Development, Inc.), Alan Rong (Astellas)
Three steps toward dose optimization for oncology dose finding
12:05 PM - 12:20 PM
Jason JZ Liao (Incyte Corporation)

Session participants

Elena Polverejan (Johnson & Johnson-Janssen R&D)
Participant
↑